Overview

Our ALIGHT(TM) technology helps neurosurgeons who want to provide patients with a better outcome than at most 18 months survival current average. By counteracting the spread of tumour-maintaining cells which ‘hitch-hike’ rapidly through healthy tissue and by giving existing treatments a better chance to take on the cancer without trading off quality of life.